Home / Market News / $SNDX
benzinga Corporate Catalyst Impact 95/100 ● negative

Syndax Pharmaceuticals shares are trading lower after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.

Oct 12, 2026, 8:05 PM UTC · Primary ticker $SNDX

This news is a major negative catalyst for Syndax Pharmaceuticals, as the failure of a key Phase 2 trial directly impacts the company's future revenue potential and drug pipeline. The stock is expected to experience a significant decline due to this setback, reflecting investor disappointment and increased uncertainty.

The failure of the MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis is a critical blow to Syndax Pharmaceuticals. Clinical trial results, especially for primary endpoints, are direct indicators of a drug's potential market viability and a company's future earnings. This negative outcome will likely lead to a sharp sell-off in SNDX shares as investors re-evaluate the company's pipeline and growth prospects. The biotechnology sector is inherently risky, with stock valuations heavily dependent on successful drug development, making such failures particularly impactful. Trading implications include potential short-selling opportunities for SNDX and a cautious sentiment across the broader biotech industry, especially for companies with similar drug candidates or in early-stage development.

$SNDX negative Primary subject of failed trial
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.